Previsioni

Il prezzo obiettivo medio degli analisti è 3,02 € (+164,91%). La mediana è 3,02 € (+164,91%).

Acquista	5
Mantieni	6
Vendi	1

Notizie Vai al feed delle notizie

ADC Therapeutics beats Q2 forecasts, stock falls after FDA concerns over LOTIS‑5

ADC Therapeutics reported adjusted Q2 EPS of -$0.11 (forecast -$0.22) and revenue of $19.25 million (expectation $18.89 million), with net product revenue for ZYNLONTA at $18.6 million (+2.8% y/y). Despite the stronger results, the stock fell in pre-market trading after the FDA raised significant benefit‑risk concerns about the LOTIS‑5 combination study (ZYNLONTA plus Rituximab). Management emphasized that ZYNLONTA monotherapy remains unaffected, that accelerated approval is still expected, and that liquidity of $219.1 million should last at least until 2028. The company has cut costs, reduced the workforce by about 17% and expects annual savings of roughly $10 million, but is evaluating further measures to resolve the regulatory concerns and the next steps for its clinical programs. » Altro su de.investing.com
ADC Therapeutics shares plunge after safety concerns in Phase‑3 LOTIS‑5 study

ADC Therapeutics' stock fell about 45.9% in after‑hours trading following publication of the topline results from the Phase‑3 LOTIS‑5 study. ZYNLONTA plus rituximab met the primary endpoint with a median progression‑free survival of 6.1 vs. 4.7 months and showed higher overall and complete response rates, but demonstrated significant safety issues. The combination arm experienced more serious adverse events (49.0% vs. 34.5%), higher treatment‑related deaths (Grade 5: 13.2% vs. 4.6%, predominantly ≥75‑year‑olds) and more treatment discontinuations (25.5% vs. 9.1%). ADC Therapeutics plans to discuss the benefit‑risk profile with the FDA, has a preparatory meeting scheduled for August and is targeting an sBLA submission in Q4 2026. » Altro su de.investing.com
ADC Therapeutics: phase‑3 study of ZYNLONTA reaches primary endpoint

The phase‑3 LOTIS‑5 study of ZYNLONTA plus rituximab met its primary endpoint for progression‑free survival (hazard ratio 0.73; p = 0.008), median PFS 6.1 vs. 4.7 months in the control arm. Overall survival showed no worsening (HR 0.96); overall response rate and complete remission rate were substantially higher than in the control arm. Serious adverse events and treatment‑related deaths (grade 5) occurred more frequently in the ZYNLONTA arm, especially in patients ≥75 years, which worried investors and pressured the share price. ADC Therapeutics plans to discuss the benefit‑risk profile with the FDA, expects a meeting in August and aims for an sBLA submission in Q4 2026; analyst targets in the report range from $6 to $10. » Altro su de.investing.com

Dati finanziari dell'azienda

Nell'ultimo trimestre, ADC THERAP. CL.C SF-,064 ha registrato ricavi pari a 16,87 Mln € e un utile netto di -14,51 Mln €

(EUR)	giugno 2026	YoY
Ricavi	16,87 Mln	5,52%
Utile lordo	14,81 Mln	3,06%
Utile netto	-14,51 Mln	69,80%
EBITDA	-40,26 Mln	14,20%

Dati fondamentali

Metrica	Valore
Capitalizzazione di mercato	125,1 Mln €
Numero di azioni	127,19 Mln
Massimo/minimo a 52 settimane	4,30 € - 0,67 €
Dividendi	No
Beta	1,84
Rapporto P/E	-1,72
Rapporto PEG	-0,02
Rapporto P/B	-0,77
Rapporto P/S	1,84

Profilo aziendale

ADC Therapeutics SA, ein Biotechnologieunternehmen im kommerziellen Stadium, entwickelt Antikörper-Wirkstoff-Konjugate (ADC) für Patienten, die an hämatologischen Malignomen und soliden Tumoren leiden. Das Hauptprodukt des Unternehmens, ZYNLONTA, befindet sich in einer klinischen Studie der Phase II zur Behandlung des rezidivierenden oder refraktären diffusen großzelligen B-Zell-Lymphoms (DLBCL) und des follikulären Lymphoms, in einer klinischen Studie der Phase III in Kombination mit Rituximab zur Behandlung des rezidivierenden oder refraktären DLBCL bei Patienten, die für eine Transplantation in zweiter Linie in Frage kommen, sowie in einer klinischen Studie der Phase I zur Behandlung des rezidivierenden oder refraktären Non-Hodgkin-Lymphoms (NHL). Das Unternehmen entwickelt außerdem Camidanlumab Tesirin, ein ADC, das die klinische Phase I zur Behandlung von rezidiviertem oder refraktärem NHL abgeschlossen hat, sich in der klinischen Phase II zur Behandlung von rezidiviertem oder refraktärem Hodgkin-Lymphom und in der klinischen Phase Ib zur Behandlung ausgewählter fortgeschrittener solider Tumore befindet. Darüber hinaus entwickelt es ADCT-602, das sich in einer klinischen Phase-Ia-Studie zur Behandlung von akuter lymphatischer Leukämie befindet, ADCT-601 und ADCT-901, die sich in einer klinischen Phase-Ia-Studie zur Behandlung verschiedener solider Tumore befinden, sowie präklinische Produktkandidaten, darunter ADCT-701 und ADCT-901 zur Behandlung solider Tumore. Das Unternehmen hat Kooperations- und Lizenzvereinbarungen mit Genmab A/S, Bergenbio AS, Synaffix B.V., Mitsubishi Tanabe Pharma Corporation, Overland Pharmaceuticals und MedImmune Limited. ADC Therapeutics SA wurde im Jahr 2011 gegründet und hat seinen Hauptsitz in Epalinges, Schweiz.

Nome	ADC THERAP. CL.C SF-,064
CEO	Ameet Mallik
Sede centrale	Epalinges, vd Svizzera
Sito web	adctherapeutics.com
Settore	Materiali
Industria	Prodotti chimici
Quotazione in borsa	18/05/2020
Dipendenti	191